Our promise to patients:
High medical impact, responsibly priced drugs

Our audacious mandate

Contribute to a more sustainable healthcare system
Develop treatments neglected or shelved by other companies
Prioritize drug projects with great therapeutic potential vs profit potential
Run a thriving business serving the public health

The Commission on Financing a Public Benefit Biotech Industry

This mandate makes Audacity Therapeutics a new type of biotech company, one among an emerging cadre with similar business models. We require an alternative financing system aligned to our purpose. Learn more about the Commission.

Money corrupting pharmaceutical industry. Click this image to read our report

Read Our OpEd in STAT NewsWhy the U.S. needs a public benefit biopharma industry

Our way

We are a Public Benefit pharmaceutical company.

We seek a new community of people and companies who also want to produce great medicines for our common health and economic welfare.

Our mission requires us to redress each element of contemporary business models to meet our mission — from utilizing strategic financing to alternative distribution channels.

Be complementary, not competitive

Advance shelved products that could help some patients, but aren’t being advanced by traditional biopharma companies
Repurpose approved drugs for different indications
Pick up drug candidates partially developed by academic labs that will not meet venture capital nor large pharmaceutical company interests
Be diligent to make our products reliable – we aren’t in a race to be first, but we are in a race to help more patients
Collaborate to be smarter and better – everyone wins

Think like engineers

Solve medical problems with sensible solutions
Be practical, efficient, rigorous and lean
Look again at prior studies — what we can learn through today’s lens?

See “Our Way” applied to a new – and old – treatment for Multiple Sclerosis

Integrate patients into our work. All steps. All the time.

Bring patients and advocates into the lab, not just the lobby
Scientists can listen to learn about the disease experience – from the experiencer
Patient’s perspectives belong in all conferences with regulators
Do “direct to patients” communication about our products – without the hype

Stand up for affordability

Premium pricing violates the Hypocratic oath: “do no harm”
An impact investment model enables rational pricing
Collaborate to create cost effective practices for developing, marketing and delivering our medicines

Be transparent — in everything we do

Be an open book scientifically and financially
By sharing – whatever the results – our fellow drug developers can learn with us
Not competing allows us to be completely transparent
Be fearless. Share openly. Trust.

“B” Responsible

We are a B Corporation (Public Benefit Corporation), part of a global movement of businesses that balance purpose and profit to grow a “B” economy — with shared and durable prosperity for all. Join us!